Interpace Biosciences, Inc. Files Amendment No. 1 to Annual Report on Form 10-K: Key Investor Highlights

Interpace Biosciences, Inc. (the “Company”) has filed Amendment No. 1 to its Annual Report on Form 10-K/A for the fiscal year ended December 31, 2025. This amendment contains information that investors and shareholders should review closely, as it includes new and updated disclosures that may be significant for share valuation and corporate governance.

Key Points from the Filing

• Purpose of Amendment:
  The amendment was filed to include Part III information (Items 10-14) that was intended to be incorporated by reference from the Company’s definitive proxy statement. The proxy statement will not be filed within 120 days after the fiscal year-end, necessitating this amendment.
• Scope of Amendment:
  The amendment replaces and restates in full Items 10 (Directors, Executive Officers, and Corporate Governance), 11 (Executive Compensation), 12 (Security Ownership), 13 (Certain Relationships and Related Transactions), and 14 (Principal Accounting Fees and Services), as well as Part IV (Exhibits and Financial Statement Schedules).
• Certification:
  The amendment includes new certifications from the principal executive and financial officers pursuant to Section 302 of the Sarbanes-Oxley Act, but not Section 906 certifications, as there are no new financial statements in the amendment.
• No New Financial Statements:
  The amendment does not contain updated financial statements. The original filing continues to speak as of its original date, and the amendment does not reflect subsequent events or updates, except as noted in the amendments.

Important Information for Shareholders

• Outstanding Shares:
  As of April 15, 2026, there were 27,700,904 shares of common stock, \$0.01 par value per share, issued and outstanding.
• Security Ownership:
  The amendment provides a detailed table of beneficial ownership as of April 15, 2026, including details about major shareholders, directors, and executive officers. Notably:
  • Ampersand 2018 Limited Partnership reported ownership of 13,861,386 shares based on a February 2026 SEC filing, representing a significant portion of outstanding shares.
  • 1315 Capital reported ownership of 9,405,941 shares as per a February 2026 SEC filing.
  • Certain executive officers and directors have rights to acquire additional shares through exercisable stock options and RSUs within 60 days of April 15, 2026.
• Equity Compensation Plans:
  The Company disclosed that, as of December 31, 2025, there were 396,222 securities to be issued upon exercise of outstanding options, warrants, and rights, with a weighted-average exercise price of \$7.30. There are 1,851,870 securities remaining available for future issuance under approved equity compensation plans.
• Insider Trading Policy:
  The Company adopted a new Insider Trading Policy in March 2025. This policy strictly prohibits employees, directors, officers, and certain consultants from trading on material nonpublic information, pledging Company securities as collateral, engaging in hedging or monetization transactions, or trading in derivative securities related to Company stock. The Company itself will not engage in securities transactions while in possession of material nonpublic information except as permitted by law.
• Corporate Governance:
  The Board has adopted a written Code of Business Conduct covering all directors, officers, employees, and consultants. This document, along with the Board’s Corporate Governance Guidelines and the Insider Trading Policy, are available on the Company’s website. Any amendments or waivers to the Code of Business Conduct will be disclosed via Form 8-K or the Company website.
• Board Structure and Committees:
  The amendment provides updated information on the composition and governance of the Board, including the Audit Committee, Nominating Committee, and Regulatory Compliance Committee. The Regulatory Compliance Committee charter can be accessed online.
• Executive Compensation:
  Detailed narrative and tabular disclosures are provided regarding the base salaries, cash incentives, equity incentives, and perquisites for key executives. Notably, 125,000 RSUs are performance-based and vest only if the share price stays at or above \$11.34 for 30 consecutive trading days, representing a potentially significant dilution event if the stock price appreciates substantially.
• Related Party Transactions:
  All transactions since January 1, 2024, involving directors, executive officers, or 5%+ shareholders and exceeding the greater of \$120,000 or 1% of average total assets are disclosed as required.
• Legal Proceedings:
  The Company has disclosed any material legal proceedings involving directors, officers, or affiliates as required.
• Exhibits:
  The amendment lists all material contracts, governance documents, equity plans, and related exhibits incorporated by reference, many of which are accessible via provided SEC hyperlinks.

Potentially Price-Sensitive Developments

• Large Shareholder Concentration:
  The significant holdings by Ampersand 2018 Limited Partnership and 1315 Capital could impact share price volatility or corporate control dynamics, especially in the event of further share accumulations, dispositions, or activist activity.
• Performance-Based RSUs:
  The issuance of 125,000 performance-based RSUs, which vest only if the stock price remains above \$11.34 for 30 consecutive trading days, could create substantial dilution for existing shareholders if performance targets are met, especially if the share price is currently below this threshold.
• No New Financial Statements:
  While not price-sensitive per se, investors should note that the amendment does not update the Company’s financials. The original annual report remains the primary source for financial information.
• Insider Trading and Governance Reforms:
  The adoption of a stricter insider trading policy and regular updates to governance documents may positively influence investor confidence and share value by reducing the risk of regulatory breaches.

Conclusion

Interpace Biosciences’ filing of this comprehensive amendment is a procedural but important development, ensuring compliance and transparency for shareholders. Investors should review the updated disclosures on executive compensation, beneficial ownership, and governance, as these may have implications for future share performance, especially in light of potential dilution from performance-based equity awards and the influence of large institutional holders.

Disclaimer: This summary is for informational purposes only and does not constitute investment advice. Investors should consult the full SEC filings and their financial advisors before making any investment decisions. The Company’s financial position and business outlook are subject to risks and uncertainties as detailed in its filings.

View INTERPACE BIOSCIENCES, INC. Historical chart here